Abstract

The effects of heterogeneous infection, vaccination and boosting histories prior to and during pregnancy have not been extensively studied and are likely important for protection of neonates. We measure levels of spike binding antibodies in 4600 patients and their neonates with different vaccination statuses, with and without history of SARS-CoV-2 infection. We investigate neutralizing antibody activity against different SARS-CoV-2 variant pseudotypes in a subset of 259 patients and determined correlation between IgG levels and variant neutralizing activity. We further study the ability of maternal antibody and neutralizing measurements to predict neutralizing antibody activity in the umbilical cord blood of neonates. In this work, we show SARS-CoV-2 vaccination and boosting, especially in the setting of previous infection, leads to significant increases in antibody levels and neutralizing activity even against the recent omicron BA.1 and BA.5 variants in both pregnant patients and their neonates.

Here the authors show that SARS-CoV-2 vaccination and boosting, especially in the setting of previous infection, leads to significant increases in antibody levels and neutralizing activity against omicron BA.1 and BA.5 variants in both pregnant patients and their neonates.

Details

Title
SARS-CoV-2 vaccination, booster, and infection in pregnant population enhances passive immunity in neonates
Author
Murphy, Elisabeth A. 1 ; Guzman-Cardozo, Camila 2 ; Sukhu, Ashley C. 3 ; Parks, Debby J. 2   VIAFID ORCID Logo  ; Prabhu, Malavika 4 ; Mohammed, Iman 4 ; Jurkiewicz, Magdalena 1 ; Ketas, Thomas J. 5 ; Singh, Sunidhi 6 ; Canis, Marie 2 ; Bednarski, Eva 2 ; Hollingsworth, Alexis 6 ; Thompson, Embree M. 6 ; Eng, Dorothy 3 ; Bieniasz, Paul D. 7   VIAFID ORCID Logo  ; Riley, Laura E. 4 ; Hatziioannou, Theodora 2   VIAFID ORCID Logo  ; Yang, Yawei J. 8   VIAFID ORCID Logo 

 Weill Cornell Medicine, Department of Pathology and Laboratory Medicine, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X) 
 The Rockefeller University, Laboratory of Retrovirology, New York, US (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519) 
 New York Presbyterian/Weill Cornell Medical Center, Department of Pathology and Laboratory Medicine, New York, US (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112) 
 Weill Cornell Medicine, Department of Obstetrics & Gynecology, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X) 
 Weill Cornell Medicine, Department of Microbiology and Immunology, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X) 
 Weill Cornell Medicine, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X) 
 The Rockefeller University, Laboratory of Retrovirology, New York, US (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519); The Rockefeller University, Howard Hughes Medical Institute, New York, US (GRID:grid.134907.8) (ISNI:0000 0001 2166 1519) 
 Weill Cornell Medicine, Department of Pathology and Laboratory Medicine, New York, US (GRID:grid.5386.8) (ISNI:000000041936877X); New York Presbyterian/Weill Cornell Medical Center, Department of Pathology and Laboratory Medicine, New York, US (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112) 
Pages
4598
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2848616742
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.